MARKET

RPTX

RPTX

Repare Therapeutics Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.64
+0.62
+1.82%
Opening 15:31 06/21 EDT
OPEN
33.90
PREV CLOSE
34.02
HIGH
34.98
LOW
33.43
VOLUME
112.36K
TURNOVER
--
52 WEEK HIGH
46.44
52 WEEK LOW
21.45
MARKET CAP
1.18B
P/E (TTM)
-20.4852
1D
5D
1M
3M
1Y
5Y
Repare Therapeutics Inc (RPTX) President and CEO Lloyd Mitchell Segal Sold $1.3 million of Shares
GuruFocus News · 06/08 20:15
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that mem...
Business Wire · 06/02 11:00
Bvf Inc Buys Five Prime Therapeutics Inc, argenx SE, Cullinan Oncology Inc, Sells Cytokinetics ...
GuruFocus News · 05/18 23:38
Logos Global Management LP Buys Design Therapeutics Inc, Instil Bio Inc, Edgewise Therapeutics ...
GuruFocus News · 05/18 16:38
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and entertainment company as analysts pointed to benefits from the reopening of theme parks...
Benzinga · 05/17 03:33
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first operating loss as a listed company, as a record regulatory fine it was
Benzinga · 05/14 05:04
Repare Therapeutics Q1 EPS $(0.58)
Repare Therapeutics (NASDAQ:RPTX) reported quarterly losses of $(0.58) per share.
Benzinga · 05/13 21:25
Repare Therapeutics EPS misses by $0.04, misses on revenue
Repare Therapeutics (RPTX): Q1 GAAP EPS of -$0.58 misses by $0.04.Revenue of $0.17M misses by $0.46M.Cash and cash equivalents, restricted cash and marketable securities of $319.1M.Press Release
Seekingalpha · 05/13 21:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPTX. Analyze the recent business situations of Repare Therapeutics Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RPTX stock price target is 46.50 with a high estimate of 51.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 26.01M
% Owned: 76.36%
Shares Outstanding: 34.06M
TypeInstitutionsShares
Increased
24
2.38M
New
15
273.56K
Decreased
13
3.76M
Sold Out
13
250.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.05%
Pharmaceuticals & Medical Research
+0.83%
Key Executives
Chairman/Independent Director
Jerel Davis
President/Chief Executive Officer/Director/Primary Contact
Lloyd Segal
Chief Financial Officer/Executive Vice President
Steve Forte
Executive Vice President/Chief Scientific Officer
Michael Zinda
Executive Vice President
Maria Koehler
Independent Director
David Bonita
Independent Director
Todd Foley
Independent Director
Samarth Kulkarni
Independent Director
Briggs Morrison
Independent Director
Kevin Raidy
Independent Director
Carol Schafer
No Data
About RPTX
Repare Therapeutics Inc is a Canada-based precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations. Its approach integrates discoveries from several fields of cell biology including deoxyribonucleic acid (DNA) repair and synthetic lethality. Its SNIPRx platform combines a clustered regularly interspaced short palindromic repeats (CRISPR)-enabled gene editing target discovery method with protein crystallography, computational biology and clinical informatics.

Webull offers kinds of Repare Therapeutics Inc stock information, including NASDAQ:RPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPTX stock methods without spending real money on the virtual paper trading platform.